Monoclonal Anti-PD-L1 Antibody, Mouse IgG1 (1G1)
抗PD-L1单克隆抗体
描述/背景（Background）
Programmed death ligand 1 (PD-L1) is the principal ligand of programmed death 1 (PD-1), a coinhibitory receptor that can be constitutively expressed or induced in myeloid, lymphoid, normal epithelial cells and in cancer. A key immune checkpoint is triggered when PD-1 (programmed cell death protein 1) engages its ligand PD-L1. As a result of this interaction, T cell activation is attenuated and an active immune response is prevented.
This mechanism is often co-opted by tumors. PD-L1 is upregulated in several tumor types and contributes to the malignancy of these cancers by interacting with PD-1 and inhibiting T cell activation. In this way, the tumors avoid detection and destruction by the immune system. Accordingly, PD-1 and PD-L1 have garnered much attention for their roles in tumor immunology and as immune-based therapeutic targets.
种属（Host Species）
Mouse
克隆号（Clone）
1G1
适用方法（Application）
IHC
效价（Property）
1：500
状态（State）
Liquid
阳性对照（Positive Control）
Human Tonsil Tissues
克隆类型（Clonality）
Monoclonal
分子别名（Synonym）
PDL1, PD-L1, CD274, B7-H1, B7H1
研究领域（Research Field）
Cancer Drug Targets
抗体来源（Source）
Mouse
同种型（Isotype）
IgG
储存（Storage）
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
典型数据（Typical Data）
用户评价：
关键字： PD-L1单克隆抗体;PD-L1;Anti-PD-L1;PD-L1 Antibody;PD-L1抗体;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。